Companies · Pharma

King Therapeutics LLCNew on the radar

PHOENIX · Pharma · refined from filed group “Other

Diligence memoA one-page analyst read on King Therapeutics LLC — recommendation, valuation, rhythm, risks.
$310K
Total raised · real
1
Rounds
Latest step-up
Top 76%
Sector rank · raised
Pre-Seed
Latest stage · inferred · Wed Jun 11 2025 00:00:00 GMT+0000 (Coordinated Universal Time)

King Therapeutics LLC looks fair against its niche peers and is active on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the pharma sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Fair
  • Modeled value is 1.26× the median modeled value of Pre-Seed Pharma companies in 2025–2027 (8 peers) — value vs value, same stage and era.
  • Within the normal band (126% of peer median) for its niche.
Active
  • Last raise 13 mo ago; this sector typically re-raises about every 16 months.
  • Raising on or ahead of the sector's normal rhythm.

Procedural diagnosis est. — rule-based common-sense checks over the filing pattern, issuer name, activity cadence, and surfaced operating evidence.

Issuer-vehicle patternmedium confidence

King Therapeutics LLC behaves more like a recurring private-offering issuer than a conventional venture-backed operating company.

Issuer structure
Company-like
No recurring-offering pattern strong enough to override normal financing interpretation.
Lifecycle
1.1 yr record
Peak capital year was 2025 with $310K across 1 filings.
Market position
ahead of 25% of Pharma peers
Capital scale is ahead of 25% of Pharma peers; modeled value is above 20% of peers by modeled value. Large capital with mid-pack modeled value can signal an issuer/program profile rather than operating-company growth.
Valuation reliability
Normal applicability
Stage/dilution valuation models are weakest when the issuer is broad-sector, recurring, or vehicle-like.
Operating evidence
Sparse
No clear CEO/founder/principal role is surfaced, so operating-company confidence is lower.
Data quality
Consistent
Canonical totals and visible filing detail are broadly aligned.
What triggered this
  • Legal name looks like an issuer vehicle rather than a product company.
  • No clearly named CEO/founder/principal role in the public records surfaced here.
  • No verified homepage on the profile yet.
  • Capital program peaked in 2025: $310K across 1 filings.
  • Largest single filing was $310K on 2025-06-11.
How to read the page
  • Read this less like a startup funding journey and more like a capital-raising program.
  • Stage-based valuation and peer labels have lower applicability for this pattern.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Pharma

King Therapeutics LLC is one of 310 Pharma companies tracked from PHOENIX. By capital raised it ranks in the long tail (ahead of 25% of sector peers), and in the long tail by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

pharma

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(b)
Reg D exemption
7
Investors (latest)
2024
Year incorporated
2025-06-11
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$250K$500K$750K$1.0MPre-Seed · 2025-06-11 Raised $310K (real) Modeled valuation $807K (est)$310K$807KPre-Seed2025

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Pre-Seed$310K · 2025

Stages are modeled from round size (public records carry no series label). Ladder is contiguous — every modeled rung has a record.

Modeled valuation trajectory
$807K
Base estimate est.
$174K
Conservative case
$2.0M
Upside case
$1.7M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Pre-Seeda round under $1.0M). Valuation is modeled from stage benchmarks scaled by the pharma sector profile. Directional, not a quoted figure.

Not enough modeled valuation points to chart a trajectory.

Model inputs · modeled:benchmark-stage-stepup-v1
18%
Dilution assumption
Implied ownership sold in the financing.
25%
Survival probability
10% low · 46% high
1.80×/yr
Annual markup
2.44×/yr upside case
1.1 yr
Elapsed time used
1.1 yr actual, capped for stale marks
pharma
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
Avg between rounds
Capital velocity
1.1 yr
On record since
2025
First round
New
First-time filer
How it compares to the market

Benchmarked against 310 companies in Pharma. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 0.0× of median
This company$310K
Sector median$6.4M
Latest round — vs other Pre-Seed rounds in sector (real $, this stage) 1.0× above median
This company$310K
Sector median$307K
Modeled value — vs sector median (estimate, all stages) 0.0× of median
This company$807K
Sector median$62.5M

Raised more than 25% of sector peers (real $). Modeled value above 20% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Pre-Seed) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #3 of 8.

This companyCohort peer
$100K$1.0M$10.0M$100K$1.0M$10.0MCapital raised (log)Mizar Therapeutics, Inc. · Pre-Seed Raised $519K · modeled $1.4M (est)ReEngage Therapeutics, Inc. · Pre-Seed Raised $365K · modeled $951K (est)Dnp Therapeutics Inc · Pre-Seed Raised $470K · modeled $797K (est)Protibea Therapeutics, Inc. · Pre-Seed Raised $970K · modeled $481K (est)Thiogenesis Therapeutics, Corp. · Pre-Seed Raised $849K · modeled $302K (est)Cyana Therapeutics, LLC · Pre-Seed Raised $151K · modeled $300K (est)OncoRock Therapeutics Inc. · Pre-Seed Raised $125K · modeled $266K (est)King Therapeutics LLC (this company) Raised $310K · modeled $807K (est)King Therapeutics LLC
CompanyStageRaised · realValue · estvs peer med.
Mizar Therapeutics, Inc.Pre-Seed$519K$1.4M2.23×
ReEngage Therapeutics, Inc.Pre-Seed$365K$951K1.49×
King Therapeutics LLC this companyPre-Seed$310K$807K1.26×
Dnp Therapeutics IncPre-Seed$470K$797K1.25×
Protibea Therapeutics, Inc.Pre-Seed$970K$481K0.75×
Thiogenesis Therapeutics, Corp.Pre-Seed$849K$302K0.47×
Cyana Therapeutics, LLCPre-Seed$151K$300K0.47×
OncoRock Therapeutics Inc.Pre-Seed$125K$266K0.42×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Pre-Seed$310K2025-06-11$1.7M$807K90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Pre-Seed$310K2025-06-11
    • First recorded raise — entered as Pre-Seed.
    • 7 investors on this round.
Intelligence
Modeled next raise
$496K
Modeled next size est.range $322K$794K
Last step-up
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
David Richardson7 other2025-06
Dmitry Derkach2025-06
Isaiah Slemons2025-06
Registry & provenance

King Therapeutics LLC is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
2088073
SEC CIK
2024
Incorporated
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Hyka Therapeutics Inc.PharmaPre-Seed$307K$14.5Msame sector · same stage
Gladius Therapeutics, Inc.PharmaPre-Seed$300K$2.3Msame sector · same stage
Disrupt Pharma Tech Africa, Inc.PharmaPre-Seed$330K$15.6Msame sector · same stage
Gaingels GC Therapeutics LLCPharmaPre-Seed$340K$2.4Msame sector · same stage
Pike Therapeutics Inc.PharmaPre-Seed$275K$751Ksame sector · same stage
St. James Therapeutics Inc.PharmaPre-Seed$350K$2.7Msame sector · same stage
Sante Veritas Therapeutics IncPharmaPre-Seed$267K$12.6Msame sector · same stage
ReEngage Therapeutics, Inc.PharmaPre-Seed$365K$951Ksame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
C2 Therapeutics IncPharmaSeries A$195.1M84%
Star Therapeutics LLCPharmaSeries D+$936.1M84%
Fleet Therapeutics, Inc.PharmaSeries B$508.2M84%
Galaxy Therapeutics Inc.PharmaSeries A$92.0M83%
Cello Therapeutics, Inc.PharmaSeries A$85.1M82%
Colorado Therapeutics LLCPharmaSeries A$79.6M82%
NV Therapeutics, Inc.PharmaSeed$12.8M82%
Capstone Therapeutics Corp.PharmaSeed$130.9M82%
Frequently asked
How much funding has King Therapeutics LLC raised?
King Therapeutics LLC has raised approximately $310K in disclosed capital across 1 recorded financing round, aggregated from public filings.
What is King Therapeutics LLC's estimated valuation?
Provath's modeled valuation for King Therapeutics LLC is approximately $807K (modeled range $174K–$2.0M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is King Therapeutics LLC at?
King Therapeutics LLC's latest modeled financing stage is Pre-Seed. Its most recent recorded round closed around Wed Jun 11.
What does King Therapeutics LLC do and where is it based?
King Therapeutics LLC operates in the Pharma sector, based in PHOENIX.
Explore related

See where King Therapeutics LLC sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at King Therapeutics LLC, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.